Mer­ck and Mod­er­na to start piv­otal can­cer vac­cine tri­al

Mer­ck and Mod­er­na will be­gin their Phase III can­cer vac­cine tri­al in Au­gust, ac­cord­ing to a fed­er­al clin­i­cal tri­als data­base.

The close­ly watched tri­al could help the duo win the first per­son­al­ized can­cer vac­cine ap­proval, though that is far down the line. The shot is giv­en along­side Mer­ck’s Keytru­da to skin can­cer pa­tients af­ter surgery with the goal of stop­ping that can­cer from re­turn­ing.

In a Phase II study with 157 melanoma pa­tients, the vac­cine plus Keytru­da re­duced the risk of the can­cer re­turn­ing or death by 44% com­pared to Keytru­da alone. And fol­low-up da­ta pre­sent­ed at AS­CO’s an­nu­al meet­ing last month showed the cus­tom vac­cine plus Keytru­da re­duced the risk of pa­tients de­vel­op­ing dead­ly metas­tases by 65% com­pared to Keytru­da alone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER